ARS Pharmaceuticals, Inc. — Director's Dealing 2022

Feb 25, 2022

SEC Form 4/A — Form 4/A

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-08

Reporting Person: Hawkinson Russ (Sr. Vice President of Finance)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-08	Common Stock	P	200	$21.00	Acquired	200	Direct

Footnotes

F1: The shares were purchased in the Issuer's initial public offering.

F2: On December 8, 2020, the reporting person filed a Form 4 in which he inadvertently reported a purchase of 238 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person purchased 200 shares of the issuer's common stock.